Boston Scientific Floats Taxus Base Price; J&J Counters TAXUS IV In Court
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific is invoking clinical data from the TAXUS IV trial's diabetic patient subset to thwart Johnson & Johnson's attempt to enjoin U.S. sales of the Express2 and Taxus stents